Clinical Evaluation
Abnormal bleeding or another concern may lead to examination, transvaginal ultrasound, hysteroscopy, or additional evaluation.
Uterine Cancer Pathology Support
Understanding Your Uterine Cancer Pathology Report
Get a clearer explanation of the diagnosis, tumor type, grade, myometrial invasion, cervical stromal involvement, lymphatic or vascular invasion, margins, lymph nodes, molecular classification, and additional findings documented in your uterine pathology report.
This educational consultation explains your existing written pathology report. It does not provide a new diagnosis, written report, official document, treatment plan, or replacement for your treating clinicians.
Understand what your report documentsAnd what may still depend on surgery, imaging, molecular testing, or other clinical information.
Board-Certified PathologistProfessional pathology-report guidance
Secure Virtual AppointmentMeet online from the comfort of home
Patient-Friendly ExplanationClear language for complex report findings
Educational SupportNot a replacement for medical advice
Understanding the Process
How a Uterine Cancer Diagnosis Is Established
Uterine cancer can arise from the endometrial lining or from other uterine tissues. Endometrial carcinoma is usually diagnosed by directly sampling the endometrium, while uterine sarcomas and other less common tumors follow different diagnostic and reporting pathways.
Endometrial Sampling
An endometrial biopsy, curettage, or hysteroscopic sample collects tissue so the lining can be examined microscopically.
Pathology Diagnosis
The report may identify atypical hyperplasia or EIN, endometrial carcinoma, uterine sarcoma, or another diagnosis and specify the tumor type.
Hysterectomy Pathology
If surgery is performed, the larger specimen may document myometrial invasion, cervical involvement, other sites, margins, and lymph nodes.
“Uterine cancer” is an umbrella term. Endometrial carcinomas, carcinosarcomas, uterine sarcomas, and metastatic tumors are not interchangeable and may use different pathology reporting frameworks.
Different Reports, Different Questions
Endometrial Biopsy or Curettage Versus Hysterectomy Pathology
A biopsy or curettage can establish a diagnosis from sampled tissue. A hysterectomy examines the entire uterus and may provide information about anatomic extent that was not available in the initial sample.
Initial Tissue Sample
Biopsy or Curettage Report
A limited sample may diagnose a precursor lesion or tumor and provide an initial classification.
- Whether atypical hyperplasia, EIN, or carcinoma is identified
- Histologic type and grade when assessable
- Whether the sample is adequate for interpretation
- Immunohistochemistry or molecular studies already completed
- Limitations caused by scant, fragmented, or superficial tissue
After Uterine Removal
Hysterectomy Pathology Report
A hysterectomy specimen may provide a more complete assessment of endometrial carcinoma and its anatomic extent.
- Final histologic type, grade, and tumor size
- Myometrial invasion and cervical stromal involvement
- Uterine serosa, adnexa, and other submitted tissues
- Lymphatic or vascular invasion and margin status
- Regional lymph nodes, pathologic categories, and additional studies
Inside the Report
What Your Uterine Pathology Report May Tell You
The information available depends on the tumor family and specimen. An endometrial biopsy, curettage, hysterectomy, lymph-node specimen, and uterine sarcoma report do not provide the same set of findings.
The tumor type determines how the rest of the report is interpreted.
Endometrial carcinoma, carcinosarcoma, uterine sarcoma, cervical carcinoma involving the uterus, and metastatic disease require different diagnostic and staging frameworks.
Diagnosis and Histologic Type
The report may identify endometrioid carcinoma, serous carcinoma, clear cell carcinoma, carcinosarcoma, or another tumor type. Uterine sarcomas are classified separately.
Histologic Grade
Grade describes microscopic features and is reported differently according to tumor type. Endometrioid carcinomas commonly use FIGO grades 1 through 3.
Tumor Size
A hysterectomy report may document the greatest gross or microscopic dimension when a measurable tumor is present.
Myometrial Invasion
The report may state whether carcinoma invades the uterine muscle and whether invasion involves less than half or at least half of the myometrial thickness.
Cervical Stromal Involvement
Invasion into the connective tissue of the cervix is different from tumor involving endocervical glands alone and may affect the pT category.
Lymphatic or Vascular Invasion
The report may state whether tumor is present in lymphatic channels or blood vessels and may quantify the number of involved spaces.
Margins
Margins are reported when applicable, particularly when carcinoma involves the cervix, parametrium, paracervical tissue, or a relevant specimen edge.
Regional Lymph Nodes
When nodes are submitted, the report may distinguish isolated tumor cells, micrometastases, and macrometastases and identify pelvic or para-aortic involvement.
Need Help Understanding These Findings?
Review the terminology, key measurements, specimen limitations, invasion findings, and pending results in your existing uterine pathology report during a secure virtual consultation.
pT1aLimited to the endometrium or less than halfway into myometrium
pT1bInvades halfway or more into myometrium
pT2Invades cervical stroma without extending beyond uterus
pT3–pT4Specified local or regional extension
Complete StageRequires wider pathologic and clinical information
Understanding Tumor Extent
How Myometrial Invasion and Other Anatomic Findings Relate to pT
For endometrial carcinoma, pT categories reflect depth of invasion into the uterine muscle, cervical stromal invasion, and involvement of specified local or regional structures. Molecular and FIGO classifications may add information beyond the anatomic pT category.
Myometrial Invasion Uses a 50% Division
pT1a includes tumor limited to the endometrium or invading less than half of the myometrium. pT1b indicates invasion of half or more.
Cervical Stroma Is Different From Glandular Involvement
pT2 requires invasion of cervical stromal connective tissue. Endocervical glandular involvement alone is not classified as pT2.
Stage Is Broader Than pT
Complete staging may also use lymph-node findings, distant disease assessment, imaging, operative findings, histologic type, LVSI, molecular results, and treating-team evaluation.
Additional Pathology Findings
Features Considered With the Wider Clinical Picture
A hysterectomy report may document additional findings considered alongside tumor type, grade, myometrial invasion, molecular classification, lymph nodes, imaging, and other clinical information.
Lymphatic or Vascular Invasion
The report may distinguish no invasion, focal involvement of four or fewer spaces, and substantial involvement of five or more spaces on one slide.
Uterine Serosa and Adnexa
The report may address involvement of the uterine surface, ovaries, or fallopian tubes when these tissues are submitted.
Other Tissue Involvement
Vagina, parametrium, pelvic tissues, bladder or bowel mucosa, omentum, peritoneum, and distant sites are documented when present and sampled.
Peritoneal or Pelvic Washings
Cytology may be reported separately. A positive washing result is recorded but does not by itself change the endometrial cancer stage.
Precursor and Background Findings
Atypical hyperplasia or endometrioid intraepithelial neoplasia, adenomyosis, leiomyomas, polyps, treatment-related changes, or other findings may be documented separately from the carcinoma.
Molecular and Biomarker Results
MMR, p53, POLE, and Other Selected Studies
Molecular classification can add information to the histologic diagnosis. Results may appear in the main report, an addendum, or separate molecular and genetics documents.
Mismatch-Repair Testing
MMR immunohistochemistry or MSI testing may help classify the tumor. Loss of an MMR protein may lead to additional laboratory or genetics evaluation.
MMRMSI
p53 Immunohistochemistry
The p53 staining pattern may contribute to molecular classification when interpreted with tumor morphology and other studies.
p53IHC
POLE and Selected Biomarkers
POLE sequencing and selected tests such as ER, PR, or HER2 may be ordered according to the tumor type and clinical setting and may be reported separately.
POLEER / PR
Molecular findings do not determine treatment by themselves. Your care team combines tumor type, grade, stage, molecular classification, imaging, health history, and other clinical information. A consultation explains documented results without recommending therapy.
Questions About MMR, p53, POLE, or Addenda?
Get a patient-friendly explanation of studies already documented in your reports and identify which findings may still be pending or reported separately.
Putting the Results Together
What Is Confirmed, Pending, or Dependent on Other Information?
A uterine pathology report may answer many important questions, but it may not provide the complete clinical picture on its own.
Confirmed in the Report
Documented Pathology Findings
The diagnosis, tumor type, grade, myometrial invasion, cervical involvement, LVSI, margins, lymph nodes, and other submitted-site findings may be documented when the specimen allows.
May Still Be Pending
Addenda or Separate Results
MMR, MSI, p53, POLE, selected biomarkers, outside consultation, later surgical specimens, or germline genetic testing may still be pending or separately reported.
Requires Wider Context
Complete Stage and Treatment Planning
Complete staging and treatment decisions may also require imaging, operative findings, distant-disease assessment, health history, and evaluation by the treating care team.
How HONEST Pathology Helps
A Clearer Explanation of the Report You Already Have
A pathology report consultation helps you understand terminology and findings already documented, so you can approach conversations with your treating team with greater context and more focused questions.
Upload Your Report and Records
Submit the pathology report and relevant records requested for the consultation.
Meet Online With a Pathologist
Discuss the report during a private virtual appointment and ask questions about the documented findings.
Receive a Plain-Language Explanation
Better understand the terminology and prepare questions to discuss with your treating care team.
Consultation Scope
What the Consultation Includes and Excludes
A report explanation and a formal microscopic second opinion are different services. Clear boundaries help you choose the appropriate option.
The Consultation May Explain
- The documented diagnosis and uterine pathology terminology
- Differences between endometrial biopsy, curettage, and hysterectomy reports
- Endometrial carcinoma, carcinosarcoma, and uterine sarcoma terminology
- Tumor type, grade, myometrial invasion, and cervical stromal involvement
- LVSI, margins, regional lymph nodes, and other submitted tissues
- Molecular studies, specimen limitations, and pending results
- Questions to discuss with your treating team
The Consultation Does Not Include
- A new pathology diagnosis or replacement interpretation
- A new written report or official document
- Complete staging from the pathology report alone
- Treatment prescribing or replacement of the medical care team
- Pelvic examination, imaging interpretation, or assessment of symptoms
- Microscopic slide review unless a separate pathology second-opinion service is ordered
Choosing the Right Service
Report Consultation or Formal Pathology Second Opinion?
The right option depends on whether you need help understanding written results or an independent review of pathology slides, tissue, or digital images.
Frequently Asked Questions
Questions About Uterine Cancer Pathology Reports
These answers provide general educational information. Individual reports vary according to tumor family, specimen, procedure, prior treatment, molecular testing, and wider clinical situation.
Are uterine cancer and endometrial cancer the same?
Endometrial cancer begins in the uterine lining and is the most common uterine cancer. “Uterine cancer” is broader and can also include tumors arising from uterine muscle or connective tissue, such as uterine sarcomas.
What is the difference between a biopsy and hysterectomy pathology report?
A biopsy or curettage samples part of the endometrium and may establish the diagnosis and initial grade. A hysterectomy examines the uterus and may document myometrial invasion, cervical stromal involvement, other submitted tissues, margins, and lymph nodes.
Is uterine cancer grade the same as stage?
No. Grade describes microscopic tumor features, while stage describes anatomic extent and may incorporate additional information. The applicable grading and staging systems depend on the tumor type.
What does myometrial invasion mean?
Myometrial invasion means carcinoma has extended from the endometrial lining into the uterine muscle. The report may state whether invasion is absent, involves less than half, or involves at least half of the myometrial thickness.
What does cervical stromal involvement mean?
It means endometrial carcinoma has invaded the supportive connective tissue of the cervix. This differs from involvement of endocervical glands alone, which does not qualify as pT2.
What does lymphatic or vascular invasion mean?
It means tumor is identified within lymphatic channels or blood vessels. The report may quantify the involved spaces, and the finding is interpreted with tumor type, grade, depth of invasion, nodes, and stage.
What do POLE, MMR-deficient, p53-abnormal, and NSMP mean?
These terms describe molecular groups used in endometrial carcinoma classification. They are determined through combinations of sequencing and immunohistochemistry and should be interpreted with the histologic diagnosis and wider case.
When is a formal pathology second opinion more appropriate?
A formal second opinion may be appropriate when findings are complex, uncertain, unexpected, or when independent examination of the original slides or tissue could provide additional value.
Clearer Answers Begin Here
Understand the Findings in Your Uterine Pathology Report
Meet online with a pathologist who can explain the terminology, key findings, measurements, specimen limitations, molecular studies, and questions raised by your existing report.
Educational support only. This service does not replace your treating physician, gynecologist, gynecologic oncologist, surgeon, radiologist, genetic counselor, or medical care team.
